Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate

European Journal of Surgical Oncology

Volumn 32, Issue 9, 2006, Pages 961-963

  Goh, B K P ^a   Chow, P K H ^a   Chuah, K L ^a   Yap, W M ^a   Wong, W K ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Gastrointestinal stromal tumor; GIST; Gleevec; Imatinib; Neoadjuvant; Response

Indexed keywords

IMATINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; GASTROINTESTINAL RADIOGRAPHY; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MALE; MEDLINE; OUTCOME ASSESSMENT; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES; TREATMENT OUTCOME;

EID: 33750345871     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.06.004     Document Type: Article

References (21)

1. Eisenberg B.L., and Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 11 (2004) 465-475
2. Connolly E.M., Gaffney E., and Reynolds J.V. Gastrointestinal stromal tumors. Br J Surg 90 (2003) 1178-1186
3. Dematteo R.P., Lewis J.J., Leung D., Mudan S.S., Woodruff J.M., and Brennan M.F. Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival. Ann Surg 231 (2000) 51-58
4. Pidhorecky I., Cheney R.T., Kraybill W.G., and Gibbs J.F. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 7 (2000) 705-712
5. Ng E.H., Pollock R.E., Munsell M.F., Atkinson E.N., and Romsdahl M.M. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas: implications for surgical management and staging. Ann Surg 215 (1992) 68-77
6. Sturgeon C., Chejfec G., and Espat N.J. Gastrointestinal stromal tumors: a spectrum of disease. Surg Oncol 12 (2003) 21-26
7. Dematteo R.P., Heinrich M.C., El-Rifai W.M., and Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 33 (2002) 466-477
8. Blanke C.D., von Mehren M., Joensu H., et al. Evaluation of the molecular targeted therapy STI 571 in patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. Proc Am Soc Clin Oncol 20 (2001) 2
9. van Oosterom A.T., Judson I., Verweji J., et al. Safety and efficacy of imatinib (STI 571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 358 (2001) 1421-1423
10. Monographs in gastrointestinal stromal tumors. 2004;1(1-2).
11. Scaife C.L., Hunt K.K., Patel S.R., et al. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?. Am J Surg 186 (2003) 665-669
12. Bauer S., Hartmann J.T., Wit M., et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 117 (2005) 316-325
13. Lo S.S., Papachristou G.I., Finkelstein S.D., Conroy W.P., Schraut W.H., and Ramanathan R.K. Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case. Dis Colon Rectum 48 (2005) 1316-1319
14. Bumming P., Andersson J., Meis-Kindblom J.M., et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a center-based study of 17 patients. Br J Cancer 89 (2003) 460-464
15. Loughrey M.B., Mitchell C., Mann G.B., Michael M., and Waring P.M. Gastrointestinal stromal tumour treated with neoadjuvant imatinib. J Clin Pathol 58 (2005) 779-781
16. Katz D., Segal A., Alberton Y., et al. Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor. Anticancer Drugs 15 (2004) 599-602
17. Chacon M., Roca E., Huertas E., Loria F.S., and Domenechini E. CASE 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate. J Clin Oncol 23 (2005) 1580-1582
18. Shah J.N., Sun W., Seethala R.R., LiVolsi V.A., Fry R.D., and Ginsberg G.G. Neoadjuvant therapy with imatinib mesylate for locally advanced GI stromal tumor. Gastrointest Endosc 1 (2005) 625-627
19. Demitri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472-480
20. Fletcher J.A., Corless C.L., and Dimitrijevic S. Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). [abstract 3725]. Proc Am Soc Clin Oncol 22 (2003) 815
21. Bauer S., Lang H., Schutte J., and Hartmann J.T. Complete remission with imatinib in metastatic gastrointestinal stromal tumors. J Clin Oncol (2005) 6800-6801